Organoid-guided drug selection for recurrent small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study uses a patient's own tumor cells grown in the lab (called an organoid) to find the most effective drug for recurrent small cell lung cancer. It aims to personalize treatment after standard therapy stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have small cell lung cancer that has come back after at least one round of treatment.
- Your cancer has grown despite previous treatment (disease progression).
- You have at least one tumor that can be safely biopsied to grow organoids.
- You are well enough to undergo a biopsy and the planned treatments (ECOG performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This trial tests a new way to choose your next treatment by growing a mini version of your tumor (an organoid) in a lab and seeing which drugs kill it best. It is for people with drug-resistant non-small cell lung cancer who have already tried at least two standard treatments.
This trial compares a treatment plan guided by lab-grown tumor samples (organoids) to standard chemotherapy (topotecan) for people whose extensive-stage small cell lung cancer has come back after initial treatment. It aims to find out which approach works better for your specific cancer.
This trial grows “organoids” (mini tumor models) from your lung cancer tissue to see which drug responses are most likely. It may help match future treatments to how your tumor behaves in the lab.
This trial uses a lab-grown miniature tumor (called an organoid) from your biopsy to test which drugs might work best for your breast cancer when standard treatments have stopped working. The goal is to find a personalized treatment option that could be more effective for you.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.